Key Highlights

● Vertex Pharmaceuticals shares fell 1.77% to close at $499.74 on October 16.

● The consensus 12-month price target is $571.46, implying about 14.3% upside.

● Analysts are split 26 Buy, 5 Hold, and 1 Sell on the stock.

● Targets range from $350 to $667 across 32 analysts.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) closed at $499.74 on October 16, 2026 and is a constituent of the S&P 500. According to market data, the consensus 12-month price target from 32 analysts is $571.46, which implies potential upside of about 14.3% from the latest close. The shares fell 1.77% on Friday and the group has recently completed an acquisition and reported pipeline data. Analyst targets are forecasts, not guarantees.

What Is the Latest Analyst Price Target?

The mean analyst target is $571.46, with a median of $578 and a range from $350 to $667. At the latest close of $499.74, the consensus target suggests upside of about 14.3%, while the highest target implies 33.5% and the lowest implies -30.0%. The figures reflect data as of October 15, 2026 and may differ from other providers, which use different analyst samples and update schedules. Targets run from $350 to $667. The median ($578) is above the mean, indicating a few lower targets pull the average down.

What Are Analysts Saying?

The rating split is 26 Buy (20 Strong Buy, 6 Buy), 5 Hold, 1 Strong Sell, giving a consensus rating of Buy. Recent actions reported include the following: Bank of America Securities (Tazeen Ahmad) maintained Buy but trimmed its target from $672 to $667 on October 15, 2026; Wells Fargo (Mohit Bansal) maintained Buy at $550 the same day; BMO Capital (Evan Seigerman) maintained Buy at $600 and Citi (Geoff Meacham) raised its target from $575 to $585 on 12 October; and RBC Capital (Brian Abrahams) raised from $570 to $576 on 8 October. UBS was reported to have raised its target from $585 to $615 about three weeks ago. Individual notes may differ in timing from other sources.

What Could Help the Stock Reach the Price Target?

Trailing twelve-month revenue was $12.59 billion, up 10.2%, with net income of $4.41 billion, up 21.1%. Positive Phase 2b results for inaxaplin and the completed acquisition of Crinetics Pharmaceuticals could broaden the pipeline, and new data on Alyftrek are due at the North American Cystic Fibrosis Conference. If the consensus proves accurate, delivery against these drivers would be needed to close the gap between the share price and the average target.

What Could Prevent the Stock Reaching the Target?

Clinical trials, regulatory decisions and competition can disappoint, and an acquisition adds integration and financial risk. One analyst has a Strong Sell rating and the lowest target is $350, well below the current price. Because targets are opinions about the next twelve months, they can be revised quickly as conditions change.

What Should Investors Watch Next?

Vertex will report third-quarter 2026 results after the market close on November 2, 2026. Investors may watch cystic fibrosis revenue, guidance and pipeline updates.

The Gap Still Has Legs

The consensus target of $571.46 suggests 14.3% upside from $499.74, but it is an aggregate of individual forecasts that rely on assumptions about earnings, valuation and the wider market.